← Back to Clinical Trials
Recruiting NCT05870969

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Carcinoma, Hepatocellular
Sponsor Ruijin Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 20,000
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2023-03-01
Completion 2028-03
Interventions
Liver cancer surveillance every 3 monthsLiver cancer surveillance every 6 monthsLiver cancer surveillance annually

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Eligibility Criteria

Inclusion Criteria: 1. Voluntary participation in the clinical study; fully informed about the study and signed informed consent, willing to follow and capable of completing all trial procedures\[17\] 2. Age: 18 to 75 years old (including the cut-offs) 3. Subjects must meet at least one of the following criteria for enrollment. 1. Patients diagnosed with chronic hepatitis B in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more 2. Patients diagnosed with hepatitis C in hospital or out of hospital 3. Patients diagnosed with cirrhosis in hospital or out of hospital who meet at least one of the following criteria. 1. Liver biopsy showing cirrhosis (Ishak score ≥5 or Metavir score = 4); 2. Liver stiffness measurement (LSM) using FibroScan® (Echosens™, Paris, France) ≥12.0 kPa when TB was normal and ALT ≤ 40 IU/mL, or LSM ≥ 17.0 kPa when TB was normal and ALT \< 200 IU/mL; 3. Abdominal imaging results showing characteristic of cirrhosis

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}